Bibliography
- Kearney PM , WheltonM, ReynoldsK, MuntnerP, WheltonPK, HeJ: Global burden of hypertension: analysis of worldwide data.Lancet365 , 217–223 (2005).
- Fields LE , BurtVL, CutlerJA, HughesJ, RoccellaEJ, SorlieP: The burden of adult hypertension in the United States 1999 to 2000: a rising tide.Hypertension44 , 398–404 (2004).
- Thoenes M , NeubergerHR, VolpeM, KhanBV, KirchW, BohmM: Antihypertensive drug therapy and blood pressure control in men and women: an international perspective.J. Hum. Hypertens. (2009) (Epub ahead of print).
- Chobanian AV , BakrisGL, BlackHR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report.JAMA289 , 2560–2571 (2003).
- Mori H , UkaiH, YamamotoH et al.: Current status of antihypertensive prescription and associated blood pressure control in Japan.Hypertens. Res.29 , 143–151 (2006).
- Rodriguez-Roca GC , Pallares-CarratalaV, Alonso-MorenoFJ et al.: Blood pressure control and physicians‘ therapeutic behavior in a very elderly Spanish hypertensive population.Hypertens. Res.32 , 753–758 (2009).
- Lennard MS , SilasJH, FreestoneS, RamsayLE, TuckerGT, WoodsHF: Oxidation phenotype – a major determinant of metoprolol metabolism and response.N. Engl. J. Med.307 , 1558–1560 (1982).
- Lennard MS , TuckerGT, WoodsHF: The polymorphic oxidation of β-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Clin. Pharmacokinet.11 , 1–17 (1986).
- Zineh I , BeitelsheesAL, GaedigkA et al.: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.Clin. Pharmacol. Ther.76 , 536–544 (2004).
- Turner ST , SchwartzGL, ChapmanAB, HallWD, BoerwinkleE: Antihypertensive pharmacogenetics: getting the right drug into the right patient.J. Hypertens.19 , 1–11 (2001).
- Johnson JA , TurnerST: Hypertension pharmacogenomics: current status and future directions.Curr. Opin. Mol. Ther.7 , 218–225 (2005).
- Arnett DK , ClaasSA: Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.Pharmacogenomics10 , 1295–1307 (2009).
- Arnett DK , ClaasSA, LynchAI: Has pharmacogenetics brought us closer to ‘personalized medicine‘ for initial drug treatment of hypertension?Curr. Opin. Cardiol.24 , 333–339 (2009).
- Arnett DK , ClaasSA, GlasserSP: Pharmacogenetics of antihypertensive treatment.Vascul. Pharmacol.44 , 107–118 (2006).
- Arnett DK , DavisBR, FordCE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.Circulation111 , 3374–3383 (2005).
- Psaty BM , SmithNL, HeckbertSR et al.: Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension.JAMA287 , 1680–1689 (2002).
- Davis BR , ArnettDK, BoerwinkleE et al.: Antihypertensive therapy, the α-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.Pharmacogenomics J.7 , 112–122 (2007).
- Gerhard T , GongY, BeitelsheesAL et al.: α-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).Am. Heart J.156 , 397–404 (2008).
- Manunta P , LaveryG, LanzaniC et al.: Physiological interaction between α-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation.Hypertension52 , 366–372 (2008).
- Shin J , JohnsonJA: Pharmacogenetics of β-blockers.Pharmacotherapy27 , 874–887 (2007).
- Pacanowski MA , GongY, Cooper-DehoffRM et al.: β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension.Clin. Pharmacol. Ther.84 , 715–721 (2008).
- Lemaitre RN , HeckbertSR, SotoodehniaN et al.: [β]1- and [β]2-adrenergic receptor gene variation, [β]-blocker use and risk of myocardial infarction and stroke.Am.J. Hypertens.21 , 290–296 (2008).
- Kelley-Hedgepeth A , PeterI, KipKE et al.: The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with [β]-blockade.J. Hum. Hypertens.22 , 512–515 (2008).
- Beitelshees AL , GongY, WangD et al.: KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).Pharmacogenet. Genomics17 , 719–729 (2007).
- Turner ST , BaileyKR, FridleyBL et al.: Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic.Hypertension52 , 359–365 (2008).
- Johnson JA , BoerwinkleE, ZinehI et al.: Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.Am. Heart J.157 , 442–449 (2009).
- Caulfield M , MunroeP, PembrokeJ et al.: Genome-wide mapping of human loci for essential hypertension.Lancet361 , 2118–2123 (2003).
- Nordestgaard BG , KontulaK, BennM et al.: Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study.Pharmacogenet. Genomics.20(2) , 77–85 (2010).
- Collins F : Opportunities and challenges for the NIH – an interview with Francis Collins. Interview by Robert Steinbrook.N. Engl. J. Med.361 , 1321–1323 (2009).